The Infona portal uses cookies, i.e. strings of text saved by a browser on the user's device. The portal can access those files and use them to remember the user's data, such as their chosen settings (screen view, interface language, etc.), or their login data. By using the Infona portal the user accepts automatic saving and using this information for portal operation purposes. More information on the subject can be found in the Privacy Policy and Terms of Service. By closing this window the user confirms that they have read the information on cookie usage, and they accept the privacy policy and the way cookies are used by the portal. You can change the cookie settings in your browser.
The tumor microenvironment is a pivotal driver of tumor progression, highlighting the potential of microenvironment reversal as a promising breakthrough in cancer therapy. However, the current tumor microenvironment reversing capacity through targeted drug delivery remains limited, posing a significant challenge in the biomedical field. In this study, a materials science strategy to achieve an inherently...
Antimicrobial therapy remains one of the major global challenges, particularly in the absence of effective treatment strategies for drug‐resistant bacteria. In this study, a comprehensive treatment approach is proposed for drug‐resistant bacterial wound infections based on the development of thermal‐cascade multifunctional therapeutic systems (MTSs), spanning from the design of functional nanoscale...
Nanoparticulate Prodrugs
In article number 2301656, Xianghui Xu and co‐workers present nanoparticulate prodrugs based on bio‐responsive macromolecular drug and small‐molecular drug conjugates for tumor microenvironment heterogeneity management and therapeutic response enhancement. This nanomedicine strategy achieves site‐specific delivery of macromolecular and small‐molecular drugs within tumor tissues,...
How to break through the poor response of current drug therapy, which often resulted from tumor microenvironment heterogeneity (TMH), remains an enormous challenge in the treatment of critical diseases. In this work, a practical solution on bio‐responsive dual‐drug conjugates for overcoming TMH and improving antitumor treatment, which integrates the advantages of macromolecular drugs and small‐molecular...
Set the date range to filter the displayed results. You can set a starting date, ending date or both. You can enter the dates manually or choose them from the calendar.